Detailed Narrative
Pinnacle 345 Strategy and Vision
Jubilant Ingrevia unveiled its 'Pinnacle 345' strategy, targeting a 3x revenue growth and 4x EBITDA growth over the next five years. This translates to an ambitious revenue target of ₹12,000 crores and an EBITDA of ₹2,000 crores by FY30. The strategy emphasizes a shift towards high-margin Specialty and Nutrition businesses, aiming for a 17-20% Return on Capital Employed (ROCE) from the current 12%.
Strategic Portfolio Shift
The company is actively transforming its business mix, aiming for Specialty chemicals to constitute 60% of the portfolio by FY30, up from the current 42-43%. Similarly, the Nutrition business is targeted to grow its share from 20% to 33-67%. This shift is expected to significantly improve overall profitability and reduce reliance on commodity-driven Chemical Intermediates, which currently contribute ₹1,700 crores in revenue with an 8% EBITDA margin, targeting 10-12% by FY30.
CDMO Business as a Key Growth Driver
The CDMO business is identified as a major growth engine, projected to achieve 5x growth in the next two years and 7x growth by FY30. The company has already secured 3.5x of this growth through existing purchase orders. A significant $300 million agro CDMO contract is underway, with construction expected to be completed by October/November this year, initiating revenue generation from Q4 FY26.
Operational Excellence and Cost Optimization
Jubilant Ingrevia is focused on operational excellence, targeting an additional ₹100 crores in cost savings annually through initiatives like improved boiler efficiency (9% gain), renewable power adoption (35% target), and effluent treatment. The company has implemented nearly 200 digital interventions across its plants and supply chain, contributing to productivity improvements and aiming for a 'Lighthouse Network Award' for at least one more plant within two years.
R&D and Innovation Focus
Recognizing past underinvestment, Jubilant Ingrevia plans to double its R&D spend from the current less than 1% of revenue in the coming years. New R&D centers in Greater Noida and pilot facilities are driving innovation, particularly in fine chemicals, CDMO, and nutrition. The company is also establishing a new process safety lab to meet stringent MNC customer expectations.
Market Expansion and Customer Centricity
The company is expanding its international footprint, with the US market share growing from 4-5% to 9% and targeting 15%+ by FY27. Management is actively engaging with key customers globally, converting relationships into CDMO-oriented partnerships. This customer-centric approach, coupled with a focus on non-pyridine chemistries, is expected to drive future growth and diversification.
Sustainability and ESG Commitments
Jubilant Ingrevia maintains a strong commitment to ESG, achieving a top 5% ranking globally with an ECOVADIS gold rating and a 93%ile in the Dow Jones Sustainability Index. The company has reduced Scope 1 and 2 emissions by 6% and aims for another 6-8% reduction in the next two years. Furthermore, 95% of total waste is recycled, and a target of 20% workforce diversity is set for the next 3-4 years.